Foresee Pharmaceuticals Signs Exclusive License Agreement with Accord Healthcare

Tuesday, Feb 12, 2019

An exclusive licensing agreement has been awarded to Accord Healthcare, which deals with the commercialization of Foresee Pharmaceuticals' new FP-001 (leuprorelin deposit) program (6576.TWO). namely, subcutaneous and ready-to-use deposition formulations of the leuprolide mesylate suspension (LMIS).

Under the terms of the partnership, Foresee, a biopharmaceutical company based in Taiwan and the United States, will receive a combination of upfront payments and milestone payments over regulatory and sales milestones, up to US $ 86 million, to which will be added a significant portion of the revenue generated by the product in the territory. Accord Healthcare, a global biopharmaceutical company, will assume all marketing costs in the territory.

The licensing agreement will cover the global market with the exception of the United States, mainland China, Japan, Taiwan and previously partner territories Israel, Turkey and some Middle Eastern countries.

Dr. Ben Chien , founder and executive chairman of Foresee, commented on this: "We are very pleased to have forged this collaboration with Accord. Given the company's strong track record in successful registrations and launches of complex oncology and specialty products, we are confident that it will be very successful in its market with our FP-001 portfolio. Accord has a great commercial team and infrastructure and we have great confidence in its ability to leverage its commercial platform. "

James Burt , Executive Vice President for Europe , said: "Accord is working hard to bring complex and value-added medicines to the market, improve the quality of care and, therefore, the lives of patients. This agreement will add another essential treatment to our already important franchise in oncology and our global reach will enable patients and healthcare providers to access this cancer treatment that makes the difference. We expect the collaboration with Foresee to be fruitful and mutually beneficial. "



Other News